Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk - PubMed (original) (raw)
doi: 10.1207/s15327914nc5601_5.
James I Taylor, Philip B Grace, Angela A Mulligan, Ailsa A Welch, Serena Scollen, Alison M Dunning, Robert N Luben, Kay-Tee Khaw, Nick E Day, Nick J Wareham, Sheila A Bingham
Affiliations
- PMID: 17176215
- DOI: 10.1207/s15327914nc5601_5
Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk
Yen-Ling Low et al. Nutr Cancer. 2006.
Abstract
Prospective phytoestrogen exposure was assessed using both biomarkers and estimates of intake in 89 British men recruited into the Norfolk arm of the European Prospective Investigation into Cancer and Nutrition study, men who subsequently developed prostate cancer. Results were compared with those from 178 healthy men matched by age and date of recruitment. Levels of seven phytoestrogens (daidzein, genistein, glycitein, O-desmethylangolensin, equol, enterodiol, and enterolactone) were measured in spot urine and serum samples. Five single-nucleotide polymorphisms in COMT, CYP19, ESR1, and SHBG genes were genotyped. Urinary levels of all phytoestrogens correlated strongly with serum levels. Correlation coefficients ranged from 0.63 (glycitein) to 0.88 (daidzein) (P < 0.001). Urinary and serum levels correlated significantly with isoflavone intake assessed from food diaries (R = 0.15-0.20; P < 0.05) but not with that from a food-frequency questionnaire. Odds ratios for phytoestrogen exposure, as assessed using the four methods, were not significantly associated with prostate cancer risk (P = 0.15-0.94). Men with the CC genotype for the ESRI PvuII polymorphism had significantly higher risk for prostate cancer compared with men with the TT genotype [adjusted odds ratio = 4.65 (1.60-13.49); P = 0.005]. Our results utilizing a combined prospective exposure provide no evidence that phytoestrogens alter prostate cancer risk in British men, whereas the C allele for the PvuII polymorphism may be associated with increased risk.
Similar articles
- ESR1 Gene Polymorphisms and Prostate Cancer Risk: A HuGE Review and Meta-Analysis.
Wang YM, Liu ZW, Guo JB, Wang XF, Zhao XX, Zheng X. Wang YM, et al. PLoS One. 2013 Jun 21;8(6):e66999. doi: 10.1371/journal.pone.0066999. Print 2013. PLoS One. 2013. PMID: 23805288 Free PMC article. Review. - Polymorphisms in the CYP19 gene may affect the positive correlations between serum and urine phytoestrogen metabolites and plasma androgen concentrations in men.
Low YL, Taylor JI, Grace PB, Dowsett M, Folkerd E, Doody D, Dunning AM, Scollen S, Mulligan AA, Welch AA, Luben RN, Khaw KT, Day NE, Wareham NJ, Bingham SA. Low YL, et al. J Nutr. 2005 Nov;135(11):2680-6. doi: 10.1093/jn/135.11.2680. J Nutr. 2005. PMID: 16251630 - Phytoestrogen exposure correlation with plasma estradiol in postmenopausal women in European Prospective Investigation of Cancer and Nutrition-Norfolk may involve diet-gene interactions.
Low YL, Taylor JI, Grace PB, Dowsett M, Scollen S, Dunning AM, Mulligan AA, Welch AA, Luben RN, Khaw KT, Day NE, Wareham NJ, Bingham SA. Low YL, et al. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):213-20. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 15668497 - Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition-norfolk.
Grace PB, Taylor JI, Low YL, Luben RN, Mulligan AA, Botting NP, Dowsett M, Welch AA, Khaw KT, Wareham NJ, Day NE, Bingham SA. Grace PB, et al. Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):698-708. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15159299 - Phytoestrogen consumption and association with breast, prostate and colorectal cancer in EPIC Norfolk.
Ward HA, Kuhnle GG. Ward HA, et al. Arch Biochem Biophys. 2010 Sep 1;501(1):170-5. doi: 10.1016/j.abb.2010.05.018. Epub 2010 Jun 1. Arch Biochem Biophys. 2010. PMID: 20494649 Review.
Cited by
- An improved PSO algorithm for generating protective SNP barcodes in breast cancer.
Chuang LY, Lin YD, Chang HW, Yang CH. Chuang LY, et al. PLoS One. 2012;7(5):e37018. doi: 10.1371/journal.pone.0037018. Epub 2012 May 18. PLoS One. 2012. PMID: 22623973 Free PMC article. - Urinary phytoestrogen excretion and prostate cancer risk: a nested case-control study in the Multiethnic Cohort.
Park SY, Wilkens LR, Franke AA, Le Marchand L, Kakazu KK, Goodman MT, Murphy SP, Henderson BE, Kolonel LN. Park SY, et al. Br J Cancer. 2009 Jul 7;101(1):185-91. doi: 10.1038/sj.bjc.6605137. Epub 2009 Jun 16. Br J Cancer. 2009. PMID: 19536097 Free PMC article. - ESR1 Gene Polymorphisms and Prostate Cancer Risk: A HuGE Review and Meta-Analysis.
Wang YM, Liu ZW, Guo JB, Wang XF, Zhao XX, Zheng X. Wang YM, et al. PLoS One. 2013 Jun 21;8(6):e66999. doi: 10.1371/journal.pone.0066999. Print 2013. PLoS One. 2013. PMID: 23805288 Free PMC article. Review. - Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
Sissung TM, Danesi R, Kirkland CT, Baum CE, Ockers SB, Stein EV, Venzon D, Price DK, Figg WD. Sissung TM, et al. J Clin Endocrinol Metab. 2011 Feb;96(2):E368-72. doi: 10.1210/jc.2010-2070. Epub 2010 Nov 24. J Clin Endocrinol Metab. 2011. PMID: 21106711 Free PMC article. - Phytoestrogenic isoflavonoids in epidemiologic and clinical research.
Franke AA, Halm BM, Kakazu K, Li X, Custer LJ. Franke AA, et al. Drug Test Anal. 2009 Jan;1(1):14-21. doi: 10.1002/dta.12. Drug Test Anal. 2009. PMID: 20355154 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous